CONTRAST-ENHANCED ULTRASOUND IN LOCATING AXILLARY SENTINEL LYMPH NODES IN PATIENTS WITH BREAST CANCER: A PROSPECTIVE STUDY

The objective was to explore the clinical value of contrast-enhanced ultrasound (CEUS) in locating the sentinel lymph node (SLN) in patients with early breast cancer. We screened 143 consecutive patients with breast cancer between July 2017 and August 2019. The number of SLNs identified by CEUS and dual labeling (blue dye and radiolabeled colloid) were recorded. The accuracy of CEUS plus fine-needle aspiration cytology (FNAC) was assessed. The rate of identification of SLNs with CEUS was 84.0% (121/144), and that of dual labeling was 97.92% (141/144). There was no significant association between non-enhancement (p = 0.060) or inhomogeneous enhancement (p = 0.468) and lymph node metastasis. The sensitivity and specificity of CEUS-SLNs plus FNAC was 78.38% and 100%, respectively. The technique of CEUS is a promising method for locating the axillary SLN. But it is hard to identify lymph node metastasis with CEUS alone. CEUS-SLNs plus FNAC is a sound technique for diagnosis of the metastasis of SLN. (C) 2021 World Federation for Ultrasound in Medicine & Biology. All rights reserved.

Automated summary

CEUS is valuable in locating SLN in early breast cancer patients, with a lower identification rate compared to dual labeling with FNAC. The technique shows promise in locating axillary SLNs, but is not reliable for identifying lymph node metastasis without FNAC confirmation.